文献速递心力衰竭与心肌病血脂与心血管预防

卡格列净对2型糖尿病患者心力衰竭的影响:CANVAS项目结果

Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program.
PubMed 文献 · Circulation · 2018-01-01

卡格列净降低心血管死亡或心力衰竭住院风险(HR 0.78,95%CI 0.67-0.91),基线有心力衰竭病史者获益可能更大(HR 0.61,交互P=0.021)。

要点

  • 基线有心衰病史者获益更显著,交互P=0.021。
  • 致死性或住院性心衰及单纯心衰住院风险均降低。

核心结论

  • 在2型糖尿病且心血管风险升高的患者中,卡格列净降低心血管死亡或心力衰竭住院风险,且在不同亚组中一致。

主要发现

  • 卡格列净组心血管死亡或心衰住院发生率为16.3/1000患者年,安慰剂组为20.8/1000患者年(HR 0.78,95%CI 0.67-0.91)。
  • 致死性或住院性心衰HR 0.70(95%CI 0.55-0.89),单纯心衰住院HR 0.67(95%CI 0.52-0.87)。
  • 基线有心衰病史者心血管死亡或心衰住院HR 0.61(95%CI 0.46-0.80),无心衰病史者HR 0.87(95%CI 0.72-1.06),交互P=0.021。
  • 基线有心衰病史者占14.4%,更多为女性、白人、高血压及既往心血管疾病患者(均P<0.001)。
  • 除渗透性利尿相关事件绝对发生率可能降低(P=0.03)外,其他心血管结局和关键安全结局在有/无心衰病史者中相似(交互P均>0.130)。

临床怎么用

  • 对于2型糖尿病伴高心血管风险患者,可考虑使用卡格列净以降低心衰住院和心血管死亡风险。
  • 基线有心力衰竭病史的患者可能从卡格列净治疗中获益更大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Canagliflozin is a sodium glucose cotransporter 2 inhibitor that reduces the risk of cardiovascular events. We report the effects on heart failure (HF) and cardiovascular death overall, in those with and without a baseline history of HF, and in other participant subgroups. METHODS: The CANVAS Program (Canagliflozin Cardiovascular Assessment Study) enrolled 10 142 participants with type 2 diabetes mellitus and high cardiovascular risk. Participants were randomly assigned to canagliflozin or placebo and followed for a mean of 188 weeks. The primary end point for these analyses was adjudicated cardiovascular death or hospitalized HF. RESULTS: Participants with a history of HF at baseline (14.4%) were more frequently women, white, and hypertensive and had a history of prior cardiovascular disease (all P<0.001). Greater proportions of these patients were using therapies such as blockers of the renin angiotensin aldosterone system, diuretics, and β-blockers at baseline (all P<0.001). Overall, cardiovascular death or hospitalized HF was reduced in those treated with canagliflozin compared with placebo (16.3 versus 20.8 per 1000 patient-years; hazard ratio [HR], 0.78; 95% confidence interval [CI], 0.67-0.91), as was fatal or hospitalized HF (HR, 0.70; 95% CI, 0.55-0.89) and hospitalized HF alone (HR, 0.67; 95% CI, 0.52-0.87). The benefit on cardiovascular death or hospitalized HF may be greater in patients with a prior history of HF (HR, 0.61; 95% CI, 0.46-0.80) compared with those without HF at baseline (HR, 0.87; 95% CI, 0.72-1.06; P interaction =0.021). The effects of canagliflozin compared with placebo on other cardiovascular outcomes and key safety outcomes were similar in participants with and without HF at baseline (all interaction P values >0.130), except for a possibly reduced absolute rate of events attributable to osmotic diuresis among those with a prior history of HF ( P=0.03). CONCLUSIONS: In patients with type 2 diabetes mellitus and an elevated risk of cardiovascular disease, canagliflozin reduced the risk of cardiovascular death or hospitalized HF across a broad range of different patient subgroups. Benefits may be greater in those with a history of HF at baseline. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifiers: NCT01032629 and NCT01989754.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Rådholm K, Figtree G, Perkovic V, et al. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program. Circulation. 2018. PMID: 29526832. doi:10.1161/CIRCULATIONAHA.118.034222

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。